Can-Fite surges 50% as Brazil approves key A3AR patent

Can-Fite BioPharma shares jumped 50% pre-market after Brazil granted a patent covering its A3 adenosine receptor agonists for treating sexual dysfunction. The approval expands the company IP in a key Latin American market and supports future commercialisation. Can-Fite is also advancing its A3AR pipeline across oncology and inflammatory diseases.